A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants

Vibhu Kanchan, Khalequ Zaman, Asma Binte Aziz, Sheikh Farzana Zaman, Farzana Zaman, Warda Haque, Mahbuba Khanam, Mohammad Mahbubul Karim, Sachin Kale, Syed Khalid Ali, Michelle G Goveia, Susan S Kaplan, Davinder Gill, Wasif Ali Khan, Mohammad Yunus, Ajitpal Singh, John D Clemens, Vibhu Kanchan, Khalequ Zaman, Asma Binte Aziz, Sheikh Farzana Zaman, Farzana Zaman, Warda Haque, Mahbuba Khanam, Mohammad Mahbubul Karim, Sachin Kale, Syed Khalid Ali, Michelle G Goveia, Susan S Kaplan, Davinder Gill, Wasif Ali Khan, Mohammad Yunus, Ajitpal Singh, John D Clemens

Abstract

Objectives: To assess the safety and reactogenicity of single oral dose of heat-stable rotavirus vaccine (HSRV) in healthy adults aged 18-45 years followed by assessment of safety, reactogenicity, and immunogenicity of three doses of HSRV in healthy infants aged 6-8 weeks at enrollment.Trial Design: Single-center randomized controlled, sequential, blinded (adults) and open-label (infants).Setting: Single site at International Center for Diarrheal Disease Research, Bangladesh (icddr,b).Participants: Fifty eligible adults randomized in 1:1 ratio (HSRV: Placebo) followed by 50 eligible infants randomized in 1:1 ratio (HSRV: Comparator (RotaTeq®, pentavalent human-bovine (WC3) reassortant live-attenuated, rotavirus vaccine)).Intervention: Adults received either a single dose of HSRV or placebo and followed for 14 days. Infants received three doses of either HSRV or comparator with a follow-up for 28 days after each dose.Main Outcome Measures: Solicited and unsolicited adverse events (AEs) along with any serious adverse events (SAEs) were part of the safety and reactogenicity assessment in adults and infants whereas serum anti-rotavirus IgA response rates were part of immunogenicity assessment in infants only. Post-vaccination fecal shedding of vaccine-virus rotavirus strains was also determined in adults and infants.Results: In this study, HSRV, when compared with placebo, did not result in increase in solicited adverse events (solicited AEs) in adults. In infants, HSRV had a safety profile similar to comparator vis-à-vis solicited AEs. In infants, fecal shedding of vaccine-virus strains was not detected in HSRV recipients but was observed in two comparator recipients. Percentage of infants exhibiting threefold rise in serum anti-rotavirus IgA titers from baseline to 1-month post-dose 3 in HSRV group was 88% (22/25) and 84% (21/25) in comparator group.Conclusion: HSRV was found to be generally well-tolerated in both adults and infants and immunogenic in infants.

Trial registration: ClinicalTrials.gov NCT02728869.

Keywords: Heat stable rotavirus vaccine; immunogenicity; randomized; reactogenicity; safety.

Figures

Figure 1.
Figure 1.
Study design and plan.

References

    1. World Health Organization . Rotavirus Vaccines. WHO Position Paper, February 1, 2013.
    1. Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, Armah G, Bines JE, Brewer TG, Colombara DV, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172:958–65. doi:10.1001/jamapediatrics.2018.1960.
    1. WHO Media Centre . Global use of rotavirus vaccines recommended: vaccines can protect millions of children from diarrhoeal disease; 2009. [accessed 2019 January22].
    1. Satter SM, Gastanaduy PA, Islam K, Rahman M, Rahman M, Luby SP, Heffelfinger JD, Parashar UD, Gurley ES.. Hospital-based surveillance for rotavirus gastroenteritis among young children in Bangladesh: defining the potential impact of a rotavirus vaccine program. Pediatr Infect Dis J. 2017;36:168–72. doi:10.1097/INF.0000000000001381.
    1. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbio Rev. 2008;21:198–208. doi:10.1128/CMR.00029-07.
    1. Lokeshwar M, Bhave S, Gupta A, Goyal V, Walia A. Immunogenicity and safety of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine (PRV) in Indian infants. Hum Vac Immuno. 2013;9:172–76. doi:10.4161/hv.22341.
    1. Kang G, Arora R, Chitambar S, Deshpande J, Gupte M, Kulkarni M, Naik TN, Mukherji D, Venkatasubramaniam S, Gentsch JR, et al. Indian rotavirus strain surveillance network. Multicenter hospital-based surveillance of rotavirus disease and strains among Indian children aged< 5 years. J Infect Dis. 2009;200:S147–S153. doi:10.1086/605031.
    1. Zaman K, Yunus M, Faruque A, El Arifeen S, Hossain I, Azim T, Rahman M, Podder G, Roy E, Luby S, et al. Surveillance of rotavirus in a rural diarrhoea treatment centre in Bangladesh, 2000–2006. Vaccine. 2009;27:F31–F34. doi:10.1016/j.vaccine.2009.08.063.
    1. Rahman M, Sultana R, Ahmed G, Nahar S, Hassan ZM, Saiada F, Podder G, Faruque AS, Siddique AK, Sack DA, et al. Prevalence of G2P [4] and G12P [6] rotavirus, Bangladesh. Emerg Infect Dis. 2007;13:18–24. doi:10.3201/eid1301.060910.
    1. WHO prequalified vaccines . 2019. [accessed 2019 January22].
    1. RotaTeq® Product Insert . [accessed 2019 January22].
    1. Rotarix® Product Insert . [accessed 2019 January22].
    1. Rotavac® Product Insert . [accessed 2019 January22].
    1. Madan M, Sikriwal D, Sharma G, Shukla N, Mandyal AK, Kale S, Gill D. Rational design of heat stable lyophilized rotavirus vaccine formulations. Hum Vaccin Immunother. 2018;14:2132–41. doi:10.1080/21645515.2018.1487499.
    1. United States Food and Drug Administration . Vaccines, blood & biologics: vaccines approved products – RotaTeq® clinical review; 2006. [accessed 2019 January22]. .
    1. Centers for Disease Control and Prevention . Prevention of rotavirus gastroenteritis among infants and children. MMWR Recomm Rep. 2006;55(RR–12):1–13.
    1. Ciarlet M, Schödel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq®. Vaccine. 2009;27:G72–G81. doi:10.1016/j.vaccine.2009.09.107.
    1. Lawrence J, He S, Martin J, Schödel F, Ciarlet M, Murray AV. Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects. Hum Vaccin Immunother. 2014;10:2247–54. doi:10.4161/hv.29107.
    1. Zaman K, Anh DD, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:615–23. doi:10.1016/S0140-6736(10)60755-6.
    1. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 2008;8:642–49. doi:10.1016/S1473-3099(08)70231-7.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera